Family Medicine Doctors in Dunkirk, NY Accepting Medicare

9 Family Medicine doctors found. Showing 1 - 9

Helen Carreras-suchanick, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 19 Lake Shore Dr W, Dunkirk, NY 14048 Phone: 716-363-6377

Maxim Mitchell, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3898 Vineyard Dr, Dunkirk, NY 14048 Phone: 716-646-5500

Dr. Keith Balram Shankar, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 3898 Vineyard Dr Ste 1, Dunkirk, NY 14048 Phone: 716-363-6960

Dr. Tat- Sum Lee, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3898 Vineyard Dr, Suite 3, Dunkirk, NY 14048 Phone: 716-363-1515    Fax: 716-363-7677

Erin Elizabeth Miller, PA-C Family Medicine Medicare: Medicare Enrolled Practice Location: 319 Central Ave Ste B, Dunkirk, NY 14048 Phone: 716-363-6050

Gabriel N Attallah, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 319 Central Ave Ste B, Dunkirk, NY 14048 Phone: 716-363-6050

Eric Paul Sager, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 75 E 3rd St, Dunkirk, NY 14048 Phone: 716-363-6050    Fax: 833-974-1992

Dr. Annie Mathai, MD Family Medicine - Geriatric Medicine Medicare: Medicare Enrolled Practice Location: 504 Central Ave, Dunkirk, NY 14048 Phone: 716-366-9008    Fax: 716-366-3158

Mrs. Leslie Jean Mcnaughtan, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 75 E 3rd St, Dunkirk, NY 14048 Phone: 716-363-6050

News Archive

FDA accepts TxCell's IND application for Ovasave for treatment of refractory Crohn's disease

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.

BioMed Central launches new journal Acta Neuropathologica Communications

Open access publisher BioMed Central is proud to announce the launch of Acta Neuropathologica Communications (ANC). ANC will publish work on pathology and mechanisms of neurological disease using structural, molecular and cellular techniques.

Asahi Kasei announces commencement of tender offer for ZOLL

Asahi Kasei Corporation, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, announced today the commencement of a tender offer through its indirect wholly owned U.S. subsidiary Asclepius Subsidiary Corporation for all outstanding shares of common stock of ZOLL Medical Corporation for $93 per share, net to the seller in cash, without interest and less any required withholding taxes.

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

AMAG Pharmaceuticals, Inc. today announced that the European Commission has granted marketing authorization for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).

Read more Medical News

› Verified 2 days ago